Diamines & Chemicals Limited has announced that its board of directors will convene on March 24, 2026, to deliberate on the conversion of warrants into equity shares. The meeting has been scheduled in compliance with regulatory requirements under the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015.

Meeting Details and Purpose

The board meeting is specifically convened to consider and approve the conversion of warrants into equity shares of the company. This conversion will be executed according to the terms established during the initial warrant issuance and will accommodate the exercise of options by warrant holders on a preferential basis.

Regulatory Compliance

The company has formally communicated this development to both major stock exchanges where its shares are listed. The notification was sent to BSE Limited and National Stock Exchange of India Limited on March 17, 2026, ensuring full compliance with Regulation 29 and Chapter IV of the SEBI (LODR) Regulations 2015.

Corporate Communication

The official notice was signed by Hemaxi Pawar, Company Secretary (Membership No.: A52581), and digitally authenticated on March 17, 2026. The communication emphasizes the company's commitment to maintaining transparency with regulatory authorities and stakeholders regarding significant corporate actions.

The board meeting may also address other business matters as deemed necessary by the directors, though the primary focus remains on the warrant conversion process.

Diamines & Chemicals Limited has submitted its fund utilization disclosure to stock exchanges for the quarter ended December 31, 2025, in compliance with SEBI Regulation 32(1). The filing provides details on the deployment of funds raised through a preferential issue of convertible warrants completed in October 2024.

Fund Raising Details

The company successfully raised funds through convertible warrants with the following key parameters:

Fund Utilization Status

As of December 31, 2025, the company has utilized a portion of the raised funds according to the original allocation plan:

The funds were designated for multiple corporate purposes including capital expenditures, working capital requirements, acquisition activities, investment in technology, and general corporate purposes.

Regulatory Compliance

The disclosure confirms that there is no deviation or variation in the use of funds raised from their originally stated purposes. The company received in-principle approval on September 19, 2024, for issuing up to 916390 convertible warrants at ₹552 per warrant. The Board of Directors, in their meeting held on October 01, 2024, allotted 906390 convertible warrants upon receipt of subscription money totaling ₹12.51 crores.

Key Highlights

• No monitoring agency oversight required for this fund raising
• No comments from Audit Committee or auditors regarding fund utilization
• No deviation from original objects or allocation as disclosed to investors
• Funds being deployed as per the approved corporate purposes

The filing was signed by Company Secretary Hemaxi Pawar and submitted to both BSE Limited and National Stock Exchange of India Limited on February 12, 2026, maintaining transparency with stakeholders regarding fund deployment progress.